MedTrace Logo

Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)

NCT00845845 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2013-07-24

Study results available
· View outcomes & findings →

Summary

The current pilot study assesses the use of magnetic resonance imaging (MRI) to quantify hepatic steatosis. It will provide preliminary data regarding the use of omega-3 fatty acid supplementation (Lovaza) for the treatment of nonalcoholic steatohepatitis (NASH).

Conditions

  • Nonalcoholic Steatohepatitis (NASH)
  • Hepatic Steatosis

Interventions

DRUG

Omega-3-acid ethyl esters (Lovaza)

4 milligrams daily omega-3-acid ethyl esters (Lovaza) with dietary counseling for 24 weeks.

DRUG

Placebo

Daily placebo with dietary counseling for 24 weeks.

Sponsors & Collaborators

  • University of Illinois at Chicago

    lead OTHER

Principal Investigators

  • Scott Cotler, M.D. · University of Illinois Chicago

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2010-10-31
Completion
2010-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00845845 on ClinicalTrials.gov